In the past 5 years, major advancements have been made in the systemic therapy of advanced and metastatic melanoma. As opposed to the robust research and clinical trials in melanoma, progress in the treatment of locally advanced and metastatic keratinocyte cancers (KC), such as cutaneous squamous cell carcinomas (cSCC) and basal cell carcinomas (BCC), has been lagging behind. The first targeted therapy was successfully introduced for advanced BCC using hedgehog pathway inhibitors and demonstrated good responses and a decent adverse effects profile. In this issue of JAMA Dermatology, 3 groups of authors discuss their findings about targeted therapy for sSCC1 and immunotherapy for cSCC2 and BCC.3
Olasz EB, Babakoohi S, Lazarova Z. Keratinocyte Cancer Therapies Enter the Era of Targeted and Immunotherapy: Join the Club. JAMA Dermatol. 2017;153(4):253–255. doi:10.1001/jamadermatol.2017.0269
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: